<このテーマに関連する主な研究業績>
Taguchi T, Masuo Y, Futatsugi A, Kato Y. Static model-based assessment
of OATP1B1-mediated drug interactions with preincubation-dependent inhibitors
based on inactivation and recovery kinetics. Drug Metab Dispos 48(9): 750-758, 2020.
Sarashina A, Chiba K, Tatami S, Kato Y. Physiologically based pharmacokinetic
model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics
in humans. J Pharm Sci 109(7): 2336-2344, 2020.
Arakawa H, Sugiura S, Kawanishi T, Shin K, Toyoda H, Satoh T, Sakai Y,
Kanamori T, Kato Y. Kinetic analysis of sequential metabolism of triazolam
and its extrapolation to humans using an entero-hepatic two-organ microphysiological
system. Lab on a Chip 20(3): 537-547, 2020.
Taguchi T, Masuo Y, Sakai Y, Kato Y. Short-lasting inhibition of hepatic
uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib. Drug Metab Pharmacokinet 34(6): 372-379, 2019.
Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y. Characterization of long-lasting
Oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo
discrepancy in its drug interaction potential in rats. J Pharm Sci 105(7): 2231-2239, 2016.
Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa
M, Nakamichi N, Ishiwata N and Kato Y. Interaction of novel platelet-increasing
agent eltrombopag with rosuvastatin via breast cancer resistance protein
in human. Drug Metab Dispos 42: 726-734, 2014.
Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-Increasing agent. Drug Metab Dispos 39(6): 1088-1096, 2011.
詳細は、こちら。
詳細は、こちら。
詳細は、こちら。